ADPT | Ticker Profile - Titan Protect

ADPT

Adaptive Biotechnologies Corporation

Healthcare · Diagnostics & Research · NMS

$16.90

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.2B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-53.82

Based on estimated future earnings — lower means cheaper

Rev Growth

+35.1%

Year-over-year revenue change

Profit Margin

-16.8%

How much profit the company keeps from each dollar of revenue

ROE

-24.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$20.00

+18% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 7 analysts covering this stock

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

https://www.adaptivebiotech.com

Country: United States Employees: 624 Industry: Diagnostics & Research

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

1.327

Excellent risk-adjusted returns

Kelly Fraction

0.0958

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

2.717

Returns exceed worst-case losses — strong risk profile

Annual Return

106.9%

Historical annualised return based on price data

Max Drawdown

-39.4%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.16

Significantly more volatile than the market

52W High

$20.76

19% below the year high

52W Low

$9.05

87% above the year low

Avg Volume

1,922,368

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

7.0%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.32

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

92.84

Heavy leverage — higher financial risk if revenues decline

Current Ratio

3.35

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

3.08

Like current ratio but excludes inventory — stricter test

Gross Margin

43.7%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-27.1%

Profit from core operations before interest and tax

Free Cash Flow

$16M

Positive — the business generates more cash than it spends

Revenue (TTM)

$295M

Total revenue over the last 12 months

Net Income

$-49,680,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$22.00

Target Median

$20.00

Target Low

$18.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go